Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 5/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | CDC25A | P30304 | 3/20 | 0.62 |
| ▸ | CDC25C | P30307 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395030 | 0.84 | KDM4E (0.74) | KDM4EALDH1A1HPGDHSD17B10CDC25A | |
| SCHEMBL571861 | 0.82 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10CDC25A | |
| Hymecromone Methyl Ether SCHEMBL31103478 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10CA12 | |
| Hymecromone Methyl Ether SCHEMBL314248 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL17384225 | 0.80 | CDC25A (0.69) | KDM4EALDH1A1HPGDHSD17B10CDC25A | |
| SCHEMBL14424527 | 0.80 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL489643 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10CDC25A | |
| SCHEMBL12809788 | 0.79 | NPC1 (0.49) | KDM4EALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL31463116 | 0.79 | NPC1 (0.49) | KDM4EALDH1A1HPGDHSD17B10CA12 | |
| SCHEMBL30803821 | 0.79 | KDM4E (0.76) | KDM4EALDH1A1HPGDHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458910-B | Mitochondrial aldehyde dehydrogenase 2(ALDH2) binding polycyclic amides and their use for treating cancer | 亚倍生技制药公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3107899-B1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 (ALDH2) BINDING POLYCYCLIC AMIDES AND THEIR USE FOR THE TREATMENT OF CANCER | AVIV THERAPEUTICS INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-2970124-B1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | UNIV LELAND STANFORD JUNIOR (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-9879036-B2 | Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof | AVIV THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170057982-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 BINDING COMPOUNDS AND METHODS OF USE THEREOF | AVIV THERAPEUTICS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3107899-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 (ALDH2) BINDING POLYCYCLIC AMIDES AND THEIR USE FOR THE TREATMENT OF CANCER | Aldea Pharmaceuticals, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9370506-B2 | Modulators of aldehyde dehydrogenase and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2337563-A1 | MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF | The Board of Trustees of The Leland Stanford Junior University (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110105602-A2 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-05-05 | — | — | US | disclosed |
| WO-2010062308-A1 | MODULATORS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113423-A1 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-05-06 | — | — | US | disclosed |
| WO-2010028175-A1 | MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063100-A1 | MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-11 | — | — | US | disclosed |
| CN-101669030-A | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | UNIV LELAND STANFORD JUNIOR | 2010-03-10 | — | — | CN | disclosed |
| EP-2126574-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | The Board of Trustees of The Leland Stanford Junior University (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090082431-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-26 | — | — | US | disclosed |
| WO-2008112164-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105602-A2 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, AK2 | KDM4E 2814/4885ALDH1A1 13/4885HPGD 184/4885 |
| US-20170057982-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 BINDING COMPOUNDS AND METHODS OF USE THEREOF | ALDH2, DLD, ALDH5A1 | KDM4E 2893/4885ALDH1A1 25/4885HPGD 386/4885 |
| US-20100063100-A1 | MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF | ALDH2, ALDH3A1, ALDH1A1 | KDM4E 1841/4885ALDH1A1 3/4885HPGD 41/4885 |
| US-20090082431-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | ALDH2, ALDH5A1, AK2 | KDM4E 2814/4885ALDH1A1 13/4885HPGD 184/4885 |
| US-20100113423-A1 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof | ALDH2, ALDH3A1, ALDH1A1 | KDM4E 1876/4885ALDH1A1 3/4885HPGD 86/4885 |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, DLD | KDM4E 2145/4885ALDH1A1 68/4885HPGD 249/4885 |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | ALDH2, ALDH5A1, DLD | KDM4E 2145/4885ALDH1A1 68/4885HPGD 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.